[Combined hamartoma of the retina and retinal pigment epithelium. Anti-VEGF treatment of the associated choroidal neovascular membranes]

Arch Soc Esp Oftalmol. 2015 Feb;90(2):87-93. doi: 10.1016/j.oftal.2014.09.017. Epub 2014 Dec 10.
[Article in Spanish]

Abstract

Case report: A 58 year-old female was diagnosed with a juxtapapillary combined hamartoma of the retina and retinal pigment epithelium (CHR-RPE) in her left eye 14 years ago. Her visual acuity in that eye was 20/20. Recently, she came to our department with a sudden visual loss and metamorphopsis in her left eye. After performing funduscopy, angiography and OCT, she was diagnosed with choroidal neovascular membrane (CNVM) at lesion border, and started on antiangiogenic therapy.

Discussion: CHR-RPE, despite being a benign condition, may become complicated with severe visual impairment. Antiangiogenic therapy provides a good alternative to photodynamic therapy or laser photocoagulation for treatment of CNVM, avoiding adding iatrogenesis from these treatment to the complications associated with this pathology.

Keywords: Anti-VEGF; Choroidal neovascularization; Hamartoma; Iatrogenia; Iatrogenic; Membranas; Membranes; Neovascularización coroidea.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Female
  • Hamartoma / drug therapy*
  • Humans
  • Middle Aged
  • Ranibizumab / therapeutic use*
  • Retinal Diseases / drug therapy*
  • Retinal Neovascularization
  • Retinal Pigment Epithelium*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Ranibizumab